This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Albers, G. W. Articles by Amarenco, P. Search for Related Content PubMed PubMed Citation Articles by Albers, G. W. Articles by Amarenco, P. Related Collections Acute Cerebral Infarction Antiplatelets

(Stroke. 2001;32:2948.)
© 2001 American Heart Association, Inc.

Comments, Opinions, and Reviews

Combination Therapy With Clopidogrel and Aspirin

Can the CURE Results Be Extrapolated to Cerebrovascular Patients?

Gregory W. Albers, MD Pierre Amarenco, MD

From Stanford Stroke Center, Stanford University Medical Center, Stanford, Calif (G.W.A.), and Department of Neurology and Stroke Unit, Bichat Hospital, Paris, France (P.A.).

Correspondence to Gregory W. Albers, MD, Director, Stanford Stroke Center, Stanford University Medical Center, 701 Welch Rd, Bldg B, Suite 325, Palo Alto, CA 94304-1705.

	Introduction

 
Several antiplatelet agents with different mechanisms of action are currently available for secondary prevention of ischemic stroke. When used as a single agent, the efficacy of antiplatelet therapy is modest. Aspirin is the best-studied and most widely used antiplatelet agent for stroke prevention; however, it provides only an approximately 15% relative risk reduction for secondary prevention of stroke or other major vascular events.¹ Combining 2 antiplatelet agents with different mechanisms of action was demonstrated to provide a substantial increase in efficacy in the ESPS II study.² In this trial, the relative risk reduction for secondary stroke prevention was 37% with use of a combination of extended-release dipyridamole and aspirin. Importantly, the risk of major bleeding attributable to the combination therapy was no greater than that seen with aspirin alone.

Clopidogrel was shown to be a safe and efficacious medication for secondary prevention of vascular events in the CAPRIE study.³ In this trial, the benefit of clopidogrel over aspirin for the prevention of vascular events was a relative risk reduction of 8.7%. In addition, there was less major bleeding in the clopidogrel group, yielding a relative net benefit of about 10%. It has been assumed by many physicians that the combination of clopidogrel with aspirin may be substantially more effective than either agent alone. In fact, many patients with cerebrovascular disease are currently treated with this combination despite the absence of any substantial safety or efficacy data regarding the use of this combination in stroke or transient ischemic attack (TIA) patients. . . . [Full Text of this Article]

This article has been cited by other articles:

				J. K. Liao Secondary Prevention of Stroke and Transient Ischemic Attack: Is More Platelet Inhibition the Answer? Circulation, March 27, 2007; 115(12): 1615 - 1621. [Abstract] [Full Text] [PDF]

				A. D Brinker and L. Swartz Growth in Clopidogrel-Aspirin Combination Therapy Ann. Pharmacother., June 1, 2006; 40(6): 1212 - 1213. [Full Text] [PDF]

				M. Fisher Results of the Management of Atherothrombosis With Clopidogrel in High-Risk Patients Trial: Implications for the Neurologist Arch Neurol, January 1, 2006; 63(1): 20 - 24. [Abstract] [Full Text] [PDF]

				K. I. Paraskevas, S. S. Daskalopoulou, M. E. Daskalopoulos, and C. D. Liapis Secondary Prevention of Ischemic Cerebrovascular Disease. What Is the Evidence? Angiology, September 1, 2005; 56(5): 539 - 552. [Abstract] [PDF]

				D. G. Jamieson, A. Parekh, and M. D. Ezekowitz Review of Antiplatelet Therapy in Secondary Prevention of Cerebrovascular Events: A Need for Direct Comparisons Between Antiplatelet Agents Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2005; 10(3): 153 - 161. [Abstract] [PDF]

				J. W. Newburger, M. Takahashi, M. A. Gerber, M. H. Gewitz, L. Y. Tani, J. C. Burns, S. T. Shulman, A. F. Bolger, P. Ferrieri, R. S. Baltimore, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association Pediatrics, December 1, 2004; 114(6): 1708 - 1733. [Abstract] [Full Text] [PDF]

				P. Amarenco and G. A. Donnan Should the MATCH Results Be Extrapolated to All Stroke Patients and Affect Ongoing Trials Evaluating Clopidogrel Plus Aspirin? Stroke, November 1, 2004; 35(11): 2606 - 2608. [Full Text] [PDF]

				J. W. Newburger, M. Takahashi, M. A. Gerber, M. H. Gewitz, L. Y. Tani, J. C. Burns, S. T. Shulman, A. F. Bolger, P. Ferrieri, R. S. Baltimore, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association Circulation, October 26, 2004; 110(17): 2747 - 2771. [Abstract] [Full Text] [PDF]

				M. J. Alberts, J.D. Easton, G. W. Albers, and P. Amarenco Clopidogrel Plus Aspirin for Stroke Prevention Stroke, November 1, 2002; 33(11): 2546 - 2547. [Full Text] [PDF]